These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27084804)

  • 21. Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes.
    Ghorbani A; Bhambhani V; Christenson RH; Meijers WC; de Boer RA; Levy D; Larson MG; Ho JE
    J Am Coll Cardiol; 2018 Dec; 72(25):3246-3254. PubMed ID: 30573026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure.
    Hrynchyshyn N; Jourdain P; Desnos M; Diebold B; Funck F
    Arch Cardiovasc Dis; 2013 Oct; 106(10):541-6. PubMed ID: 24090952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heart failure and inflammation-related biomarkers as predictors of new-onset diabetes in the general population.
    Suthahar N; Meijers WC; Brouwers FP; Heerspink HJL; Gansevoort RT; van der Harst P; Bakker SJL; de Boer RA
    Int J Cardiol; 2018 Jan; 250():188-194. PubMed ID: 29074040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure.
    Stoltze Gaborit F; Bosselmann H; Kistorp C; Iversen K; Kumler T; Gustafsson F; Goetze JP; Sölétormos G; Tønder N; Schou M
    BMC Cardiovasc Disord; 2016 May; 16():117. PubMed ID: 27246703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?
    Srivatsan V; George M; Shanmugam E
    Eur J Prev Cardiol; 2015 Sep; 22(9):1096-110. PubMed ID: 25268020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple head-to-head comparison of fibrotic biomarkers galectin-3, osteopontin and gremlin-1 for long-term prognosis in suspected and proven acute heart failure patients.
    Behnes M; Bertsch T; Weiss C; Ahmad-Nejad P; Akin I; Fastner C; El-Battrawy I; Lang S; Neumaier M; Borggrefe M; Hoffmann U
    Int J Cardiol; 2016 Jan; 203():398-406. PubMed ID: 26539964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of Total Mortality and Serious Arrhythmic Events in Non-Ischemic Heart Failure Patients: The Role of Galectin-3.
    Kochi AN; Pimentel M; Andrades M; Zimerman T; Zimerman LI; Rohde LE
    Arq Bras Cardiol; 2021 Sep; 117(3):531-541. PubMed ID: 34550239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum ferritin and risk for new-onset heart failure and cardiovascular events in the community.
    Klip IT; Voors AA; Swinkels DW; Bakker SJ; Kootstra-Ros JE; Lam CS; van der Harst P; van Veldhuisen DJ; van der Meer P
    Eur J Heart Fail; 2017 Mar; 19(3):348-356. PubMed ID: 27758018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases.
    Mueller T; Leitner I; Egger M; Haltmayer M; Dieplinger B
    Clin Chim Acta; 2015 May; 445():155-60. PubMed ID: 25850080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study.
    Asleh R; Enriquez-Sarano M; Jaffe AS; Manemann SM; Weston SA; Jiang R; Roger VL
    J Am Coll Cardiol; 2019 May; 73(18):2286-2295. PubMed ID: 31072572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of short-term follow-up BNP in hospitalized patients with heart failure.
    Khanam SS; Son JW; Lee JW; Youn YJ; Yoon J; Lee SH; Kim JY; Ahn SG; Ahn MS; Yoo BS
    BMC Cardiovasc Disord; 2017 Aug; 17(1):215. PubMed ID: 28774268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND.
    van der Velde AR; Meijers WC; van den Heuvel ER; Bakker SJ; van Gilst WH; van der Harst P; Hillege H; de Boer RA
    Int J Cardiol; 2016 Nov; 222():385-390. PubMed ID: 27505321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.
    Grandin EW; Jarolim P; Murphy SA; Ritterova L; Cannon CP; Braunwald E; Morrow DA
    Clin Chem; 2012 Jan; 58(1):267-73. PubMed ID: 22110019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure.
    Lala RI; Lungeanu D; Darabantiu D; Pilat L; Puschita M
    Herz; 2018 Mar; 43(2):146-155. PubMed ID: 28235980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
    Jagodzinski A; Havulinna AS; Appelbaum S; Zeller T; Jousilahti P; Skytte-Johanssen S; Hughes MF; Blankenberg S; Salomaa V
    Int J Cardiol; 2015 Aug; 192():33-9. PubMed ID: 25985013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical risk stratification optimizes value of biomarkers to predict new-onset heart failure in a community-based cohort.
    Brouwers FP; van Gilst WH; Damman K; van den Berg MP; Gansevoort RT; Bakker SJ; Hillege HL; van Veldhuisen DJ; van der Harst P; de Boer RA
    Circ Heart Fail; 2014 Sep; 7(5):723-31. PubMed ID: 25057112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.
    Demissei BG; Cotter G; Prescott MF; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Severin TM; Wang Y; Qian M; Teerlink JR; Metra M; Davison BA; Voors AA
    Eur J Heart Fail; 2017 Aug; 19(8):1001-1010. PubMed ID: 28133908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex-Specific Associations of Cardiovascular Risk Factors and Biomarkers With Incident Heart Failure.
    Suthahar N; Lau ES; Blaha MJ; Paniagua SM; Larson MG; Psaty BM; Benjamin EJ; Allison MA; Bartz TM; Januzzi JL; Levy D; Meems LMG; Bakker SJL; Lima JAC; Cushman M; Lee DS; Wang TJ; deFilippi CR; Herrington DM; Nayor M; Vasan RS; Gardin JM; Kizer JR; Bertoni AG; Allen NB; Gansevoort RT; Shah SJ; Gottdiener JS; Ho JE; de Boer RA
    J Am Coll Cardiol; 2020 Sep; 76(12):1455-1465. PubMed ID: 32943164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal Patterns of 14 Blood Biomarker candidates of Cardiac Remodeling in Relation to Prognosis of Patients With Chronic Heart Failure-The Bio- SH i FT Study.
    Bouwens E; Brankovic M; Mouthaan H; Baart S; Rizopoulos D; van Boven N; Caliskan K; Manintveld O; Germans T; van Ramshorst J; Umans V; Akkerhuis KM; Kardys I
    J Am Heart Assoc; 2019 Feb; 8(4):e009555. PubMed ID: 30760105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of galectin-3 and plasma B type-natriuretic peptide in predicting prognosis in discharged chronic heart failure patients.
    Feola M; Testa M; Leto L; Cardone M; Sola M; Rosso GL
    Medicine (Baltimore); 2016 Jun; 95(26):e4014. PubMed ID: 27368017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.